Lymphoma Clinical Trials | Norton Healthcare Louisville, Ky.

Lymphoma Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous trials, our specialist physicians have access to innovative treatments.

Learn more about participating in a clinical trial at Norton Healthcare.

Active lymphoma trials at Norton Cancer Institute include:

Hematological Malignancies

Open-label, 2-arm, randomized, controlled Phase III trial of intravenous PI3K inhibitor copanlisib as monotherapy and in combination with rituximab, compared to rituximab monotherapy, in subjects with indolent B-cell non-Hodgkin lymphoma

Hematological Malignancies

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Hematological Malignancies

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton?s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Na?ve Subjects with Follicular Ly

Hematological Malignancies

A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin?) antibodyradionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

Hematological Malignancies

A Randomized Phase 3 Study to Evaluate the efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Na?ve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1. (ENGINE Study)

Hematological Malignancies

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Hematological Malignancies

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Hematological Malignancies

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Hematological Malignancies

Extended treatment protocol for subjects continuing to benefit from Ibrutinib after completion of Ibrutinib (PCI-32965) clinical trials.

Hematological Malignancies

Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells

Hematological Malignancies

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma

Hematological Malignancies

Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K ?/? dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory […]

Hematological Malignancies

A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL)

Hematological Malignancies

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Hematological Malignancies

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Hematological Malignancies

A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma

Hematological Malignancies

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Hematological Malignancies

A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3500

Cutaneous lymphoma: Blood cancer that starts in the skin

Why does a blood cancer start in the skin? Lymphomas are cancers of the immune system, which generally arise in lymph nodes and other lymphatic tissue.  The immune system consists of white blood cells, the […]

Read Full Story

Cancer-free patient finds hope from clinical trial

When Brenda Montgomery enrolled in a clinical trial at Norton Cancer Institute in February 2016, she hoped the new drug being researched would trounce the cancer she had battled for nine years. She also hoped [...]

Read Full Story

Norton cancer specialist’s research paves way for new FDA-approved lymphoma treatment

The U.S. Food and Drug Administration recently approved a new cancer drug that has been available only to patients enrolled by a Norton Cancer Institute physician and one other researcher nationwide. Don A. Stevens, M.D., [...]

Read Full Story
Related Stories

Cutaneous lymphoma: Blood cancer that starts in the skin

Why does a blood cancer start in the skin? Lymphomas are cancers of the immune system, which generally arise in lymph nodes and other lymphatic tissue.  The immune system consists of white blood cells, the […]

Read Full Story

Cancer-free patient finds hope from clinical trial

When Brenda Montgomery enrolled in a clinical trial at Norton Cancer Institute in February 2016, she hoped the new drug being researched would trounce the cancer she had battled for nine years. She also hoped [...]

Read Full Story

Norton cancer specialist’s research paves way for new FDA-approved lymphoma treatment

The U.S. Food and Drug Administration recently approved a new cancer drug that has been available only to patients enrolled by a Norton Cancer Institute physician and one other researcher nationwide. Don A. Stevens, M.D., [...]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.